FDA shines light on In­di­an man­u­fac­tur­er’s mis­giv­ings at one of its fa­cil­i­ties

Last month, In­di­an drug man­u­fac­tur­er Au­robindo Phar­ma let the na­tion­al stock ex­change know that they once again in­voked the ire of US reg­u­la­tors. Now the ‘Form 483’ shines a light on what ex­act­ly went wrong.

Ac­cord­ing to the form, sev­er­al ob­ser­va­tions were made at Au­robindo’s Unit VII for­mu­la­tion plant in the vil­lage of Polepal­ly, In­dia dur­ing an in­spec­tion in ear­ly May.

In­ves­ti­ga­tors found an un­ex­plained dis­crep­an­cy and a fail­ure of a batch of its com­po­nents to meet any of its spec­i­fi­ca­tions. The FDA found out spec­i­fi­ca­tion (OOS) as­say and dis­so­lu­tion re­sults had led to the re­jec­tions of four tablet batch­es which were iden­ti­fied by a lack of con­trol over com­pres­sion ma­chine set­tings.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER